1.
Emma Back MeTA Consultant MeTA country guidance note ‘Moving towards medicines data transparency, joint analysis and evidence-based policies to improve access to medicines’ 8 December 2009

2.
Purpose of the guidance note <ul><li>To provide advice and guidance to MeTA pilot countries – specifically national Secretariats and multi-stakeholder groups – as they take steps towards establishing a process of routine disclosure of key medicines data. </li></ul><ul><li>To provide some tools and examples to aid this process, share case studies and lessons from different countries, and identify potential sources of TA. </li></ul><ul><li>Broader purpose: </li></ul><ul><li>The note will help to ensure standardization of reporting across MeTA countries, which will in turn aid comparison, monitoring and evaluation . </li></ul>

3.
Proposed content <ul><li>Recap of MeTA pilot phase goals and principles </li></ul><ul><li>Purpose of guidance note in this context </li></ul><ul><li>Phased approach towards increasing transparency, [accountability,] and evidence-based policy and practice; an ongoing cycle: </li></ul><ul><li>Diagnosis </li></ul><ul><li>Setting parameters; agreeing reporting format; agreeing process </li></ul><ul><li>Data collection / submission; data assessment </li></ul><ul><li>Multi-stakeholder discussion of the data </li></ul><ul><li>Data use - including for comms, advocacy and policy development </li></ul><ul><li>Reporting and monitoring </li></ul><ul><li>Using the phased approach in practice </li></ul><ul><li>Securing additional support </li></ul>

4.
Questions for you <ul><li>Does the step-wise approach make sense? </li></ul><ul><li>Will the proposed format of the guidance note give you what you need? </li></ul><ul><li>What else would you like to see in the note? What do you need most guidance on? TA priorities? </li></ul><ul><li>Do you have any case studies or lessons you would like to share through the guidance note? </li></ul><ul><li>Any data collection / disclosure / reporting formats? </li></ul>